MedTrace Logo

Outpatient Performed Pterygium Surgery Study

NCT03037736 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2021-08-12

No results posted yet for this study

Summary

This is a randomized controlled trial of postoperative bevacizumab or 5-fluorouracil subconjunctival injections vs placebo for the recurrence of pterygia after excision using conjunctival autograft.

Conditions

  • Pterygium of Conjunctiva and Cornea

Interventions

DRUG

5-Fluorouracil

5-fluorouracil is an antimetabolite that is commonly used in glaucoma surgery to prevent postoperative scaring.

DRUG

Bevacizumab

Bevacizumab is an anti-VEGF antibody that is commonly used to prevent or treat neovascularization in retinal disorders.

DRUG

Normal saline

Normal saline will be used as the placebo.

Sponsors & Collaborators

Principal Investigators

  • Julie Schallhorn, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2020-03-01
Completion
2020-03-01
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03037736 on ClinicalTrials.gov